nevirapine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals 1904 129618-40-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nevirapine hemihydrate
  • nevirapine
  • viramune
  • nevarapine
A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
  • Molecular weight: 266.30
  • Formula: C15H14N4O
  • CLOGP: 2.72
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 58.12
  • ALOGS: -3.41
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.46 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.32 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 53 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 4, 1998 EMA Boehringer Ingelheim International GmbH
June 21, 1996 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 721.71 29.43 223 8946 22710 63457143
Viral mutation identified 678.39 29.43 130 9039 1680 63478173
Exposure during pregnancy 645.08 29.43 352 8817 155195 63324658
Abortion spontaneous 595.98 29.43 232 8937 46963 63432890
Virologic failure 570.57 29.43 113 9056 1749 63478104
Stillbirth 567.41 29.43 142 9027 6608 63473245
Foetal exposure during pregnancy 474.70 29.43 177 8992 31785 63448068
Pregnancy 314.32 29.43 137 9032 36699 63443154
Pathogen resistance 309.74 29.43 87 9082 6311 63473542
Caesarean section 284.69 29.43 103 9066 16929 63462924
Abortion induced 245.07 29.43 81 9088 10161 63469692
Stevens-Johnson syndrome 243.13 29.43 102 9067 24848 63455005
Maternal exposure during pregnancy 227.73 29.43 214 8955 219848 63260005
Premature baby 202.76 29.43 85 9084 20650 63459203
Lipodystrophy acquired 202.30 29.43 46 9123 1406 63478447
Immune reconstitution inflammatory syndrome 186.07 29.43 58 9111 6026 63473827
Portal hypertension 127.72 29.43 39 9130 3780 63476073
Acquired gene mutation 125.45 29.43 29 9140 954 63478899
Viral load increased 120.80 29.43 30 9139 1344 63478509
Maternal drugs affecting foetus 119.53 29.43 40 9129 5202 63474651
Ventricular septal defect 110.21 29.43 36 9133 4342 63475511
Supernumerary nipple 96.14 29.43 15 9154 48 63479805
Foetal death 94.03 29.43 41 9128 10939 63468914
Rash maculo-papular 91.15 29.43 57 9112 31839 63448014
Acoustic stimulation tests abnormal 89.82 29.43 15 9154 81 63479772
Mitochondrial toxicity 87.71 29.43 19 9150 462 63479391
Congenital naevus 86.10 29.43 16 9153 172 63479681
Amniotic cavity infection 83.65 29.43 22 9147 1241 63478612
Postpartum sepsis 82.87 29.43 11 9158 4 63479849
Immune reconstitution inflammatory syndrome associated tuberculosis 81.03 29.43 17 9152 353 63479500
Hepatic cytolysis 80.77 29.43 41 9128 15366 63464487
Low set ears 80.32 29.43 16 9153 254 63479599
Blood HIV RNA increased 79.58 29.43 19 9150 720 63479133
Hydrops foetalis 77.92 29.43 18 9151 590 63479263
Alanine aminotransferase increased 77.77 29.43 85 9084 103685 63376168
CD4 lymphocytes decreased 76.33 29.43 21 9148 1406 63478447
Premature delivery 73.88 29.43 49 9120 30232 63449621
Malaria 71.28 29.43 14 9155 206 63479647
Conjunctivalisation 70.59 29.43 9 9160 0 63479853
Pain 69.21 29.43 12 9157 740616 62739237
Toxic epidermal necrolysis 69.18 29.43 44 9125 25290 63454563
Drug ineffective 68.49 29.43 33 9136 1044732 62435121
Pre-eclampsia 65.09 29.43 30 9139 9103 63470750
Premature labour 64.74 29.43 33 9136 12471 63467382
Premature rupture of membranes 64.40 29.43 25 9144 4968 63474885
Hyperlactacidaemia 62.02 29.43 21 9148 2828 63477025
Nephropathy toxic 60.96 29.43 29 9140 9450 63470403
Hepatomegaly 60.46 29.43 31 9138 11858 63467995
Hemivertebra 59.22 29.43 11 9158 118 63479735
Low birth weight baby 59.02 29.43 26 9143 7103 63472750
Premature separation of placenta 57.96 29.43 18 9151 1843 63478010
Hepatitis 57.62 29.43 47 9122 39741 63440112
Foetal growth restriction 57.58 29.43 26 9143 7527 63472326
Aspartate aminotransferase increased 57.52 29.43 68 9101 90209 63389644
Placental disorder 57.36 29.43 17 9152 1487 63478366
Live birth 56.61 29.43 39 9130 25591 63454262
Hypertriglyceridaemia 55.63 29.43 24 9145 6235 63473618
Lactic acidosis 54.96 29.43 45 9124 38242 63441611
Uveal prolapse 54.90 29.43 7 9162 0 63479853
Eyelid scar 54.90 29.43 7 9162 0 63479853
Blood lactic acid increased 52.77 29.43 24 9145 7062 63472791
Varices oesophageal 52.40 29.43 19 9150 3129 63476724
Retinoblastoma 50.18 29.43 9 9160 78 63479775
Eyelid oedema 49.48 29.43 26 9143 10453 63469400
Lipoatrophy 49.15 29.43 11 9158 312 63479541
Congenital choroid plexus cyst 49.08 29.43 11 9158 314 63479539
Oligohydramnios 48.80 29.43 22 9147 6344 63473509
Neural tube defect 48.41 29.43 10 9159 192 63479661
Hepatotoxicity 47.92 29.43 41 9128 37000 63442853
Neonatal disorder 47.61 29.43 12 9157 571 63479282
Drug reaction with eosinophilia and systemic symptoms 46.96 29.43 39 9130 33797 63446056
Anaemia 46.57 29.43 119 9050 293311 63186542
Mitochondrial cytopathy 46.40 29.43 10 9159 237 63479616
Fat tissue increased 45.79 29.43 12 9157 667 63479186
Fatigue 45.71 29.43 37 9132 887991 62591862
Acute HIV infection 44.63 29.43 6 9163 3 63479850
Neutropenia neonatal 43.95 29.43 8 9161 76 63479777
Ulcerative keratitis 43.78 29.43 16 9153 2694 63477159
Jaundice 43.28 29.43 35 9134 29216 63450637
Pulmonary tuberculosis 42.39 29.43 18 9151 4499 63475354
Ultrasound antenatal screen 41.61 29.43 9 9160 217 63479636
Developmental delay 40.60 29.43 13 9156 1470 63478383
Pyrexia 40.36 29.43 154 9015 470324 63009529
Normal newborn 40.25 29.43 21 9148 8320 63471533
Left ventricular dilatation 39.37 29.43 10 9159 491 63479362
CD4 lymphocytes increased 38.90 29.43 8 9161 150 63479703
Spinocerebellar disorder 38.74 29.43 6 9163 18 63479835
Astrocytoma malignant 38.74 29.43 6 9163 18 63479835
Congenital anomaly 38.30 29.43 13 9156 1763 63478090
Atrial septal defect 37.93 29.43 19 9150 6919 63472934
Proteinuria 37.33 29.43 27 9142 19118 63460735
Portal vein thrombosis 36.89 29.43 14 9155 2616 63477237
Gamma-glutamyltransferase increased 36.72 29.43 34 9135 33997 63445856
Arthralgia 35.65 29.43 19 9150 569691 62910162
HIV antibody positive 35.28 29.43 5 9164 6 63479847
Fall 35.16 29.43 7 9162 392327 63087526
Alopecia 34.86 29.43 4 9165 337532 63142321
Nodular regenerative hyperplasia 34.40 29.43 9 9160 497 63479356
Hereditary optic atrophy 34.07 29.43 5 9164 9 63479844
Porphyria non-acute 33.87 29.43 8 9161 289 63479564
Encephalocele 33.85 29.43 7 9162 135 63479718
Foetal distress syndrome 33.66 29.43 11 9158 1327 63478526
Polydactyly 33.26 29.43 8 9161 313 63479540
Human immunodeficiency virus transmission 33.25 29.43 6 9163 54 63479799
Eosinophilia 33.18 29.43 27 9142 22729 63457124
Neonatal hepatomegaly 33.10 29.43 5 9164 12 63479841
Skin toxicity 32.08 29.43 15 9154 4699 63475154
Tuberculosis 31.92 29.43 20 9149 11191 63468662
Off label use 31.16 29.43 31 9138 674431 62805422
Genotype drug resistance test positive 30.88 29.43 8 9161 425 63479428
Fallot's tetralogy 30.76 29.43 6 9163 85 63479768
Breast disorder 30.27 29.43 12 9157 2518 63477335
Hepatic displacement 29.94 29.43 5 9164 27 63479826
Spina bifida 29.69 29.43 9 9160 850 63479003

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 797.94 19.27 191 11231 3153 34942356
Foetal exposure during pregnancy 654.74 19.27 295 11127 37806 34907703
Mitochondrial toxicity 627.46 19.27 151 11271 2548 34942961
Virologic failure 526.19 19.27 138 11284 3342 34942167
Eyelid ptosis 509.43 19.27 150 11272 5616 34939893
Viral mutation identified 479.74 19.27 124 11298 2830 34942679
Diplopia 342.29 19.27 147 11275 16696 34928813
Progressive external ophthalmoplegia 342.22 19.27 82 11340 1353 34944156
Exposure during pregnancy 289 19.27 109 11313 8825 34936684
Pathogen resistance 279.12 19.27 108 11314 9374 34936135
Drug resistance 270.41 19.27 143 11279 25784 34919725
Dandy-Walker syndrome 264.58 19.27 48 11374 171 34945338
Speech disorder developmental 215.23 19.27 62 11360 2138 34943371
Developmental delay 205.26 19.27 63 11359 2712 34942797
Pinealoblastoma 174.39 19.27 33 11389 156 34945353
Premature baby 162.42 19.27 93 11329 19540 34925969
Volvulus 155.21 19.27 45 11377 1587 34943922
Immune reconstitution inflammatory syndrome 153.65 19.27 69 11353 8690 34936819
Polydactyly 149.67 19.27 41 11381 1172 34944337
Trisomy 21 147.48 19.27 35 11387 552 34944957
Congenital central nervous system anomaly 140.33 19.27 34 11388 588 34944921
Stevens-Johnson syndrome 119.61 19.27 75 11347 18564 34926945
Ophthalmoplegia 116.09 19.27 37 11385 1803 34943706
Neurodevelopmental disorder 114.72 19.27 27 11395 410 34945099
Macrocephaly 110.67 19.27 27 11395 481 34945028
Ventricular septal defect 94.80 19.27 39 11383 3962 34941547
Caesarean section 90.75 19.27 32 11390 2132 34943377
Hydrops foetalis 87.31 19.27 25 11397 842 34944667
Portal hypertension 84.20 19.27 36 11386 4026 34941483
Brachydactyly 83.12 19.27 18 11404 183 34945326
Vanishing bile duct syndrome 79.05 19.27 24 11398 994 34944515
Ultrasound antenatal screen 78.95 19.27 21 11401 535 34944974
Attention deficit hyperactivity disorder 78.28 19.27 30 11392 2529 34942980
Blood lactic acid increased 75.42 19.27 39 11383 6689 34938820
Cleft lip and palate 72.96 19.27 22 11400 890 34944619
Acquired gene mutation 72.30 19.27 24 11398 1331 34944178
Trisomy 18 72.16 19.27 21 11401 750 34944759
Nodular regenerative hyperplasia 71.55 19.27 22 11400 951 34944558
Atrioventricular septal defect 69.59 19.27 16 11406 218 34945291
Neonatal disorder 66.30 19.27 20 11402 810 34944699
Maternal drugs affecting foetus 65.60 19.27 30 11392 3935 34941574
Gene mutation 63.56 19.27 22 11400 1386 34944123
Dyslipidaemia 63.29 19.27 36 11386 7452 34938057
Small for dates baby 62.74 19.27 29 11393 3898 34941611
Blood HIV RNA increased 62.50 19.27 21 11401 1209 34944300
Drug ineffective 61.20 19.27 37 11385 456714 34488795
Hypertriglyceridaemia 59.26 19.27 36 11386 8412 34937097
Product residue present 59.11 19.27 25 11397 2721 34942788
Osteonecrosis 57.82 19.27 44 11378 14846 34930663
Viral load increased 57.72 19.27 24 11398 2503 34943006
Multiple-drug resistance 57.66 19.27 30 11392 5209 34940300
Lipoatrophy 57.18 19.27 16 11406 495 34945014
Congenital neoplasm 56.42 19.27 10 11412 30 34945479
Off label use 52.06 19.27 37 11385 419487 34526022
Conjunctivalisation 49.19 19.27 7 11415 0 34945509
Fall 48.53 19.27 5 11417 202880 34742629
Hepatotoxicity 47.56 19.27 46 11376 21439 34924070
Varices oesophageal 45.66 19.27 23 11399 3732 34941777
Mitochondrial myopathy 45.19 19.27 11 11411 194 34945315
Laryngomalacia 44.59 19.27 12 11410 320 34945189
Low birth weight baby 43.75 19.27 29 11393 7876 34937633
Toxic epidermal necrolysis 43.56 19.27 44 11378 21602 34923907
Fanconi syndrome acquired 42.43 19.27 18 11404 1973 34943536
Speech disorder 42.43 19.27 47 11375 25639 34919870
Nephropathy toxic 41.97 19.27 34 11388 12554 34932955
Alanine aminotransferase increased 40.93 19.27 85 11337 80730 34864779
Aspartate aminotransferase increased 39.98 19.27 76 11346 67707 34877802
Abortion spontaneous 37.90 19.27 11 11411 389 34945120
HIV peripheral neuropathy 37.74 19.27 7 11415 29 34945480
Ataxia 37.12 19.27 33 11389 13820 34931689
Cerebellar hypoplasia 36.28 19.27 6 11416 10 34945499
Congenital umbilical hernia 36.22 19.27 10 11412 294 34945215
Treatment failure 36.14 19.27 59 11363 46638 34898871
Osteoporosis 35.59 19.27 31 11391 12637 34932872
Pre-eclampsia 34.53 19.27 7 11415 50 34945459
Portal vein thrombosis 34.14 19.27 19 11403 3769 34941740
Osteoporotic fracture 34.07 19.27 13 11409 1082 34944427
Hypotension 33.95 19.27 15 11407 221634 34723875
Bone metabolism disorder 33.48 19.27 9 11413 239 34945270
Pneumonia 33.19 19.27 42 11380 362585 34582924
Blood triglycerides abnormal 32.95 19.27 9 11413 254 34945255
Human immunodeficiency virus transmission 31.76 19.27 6 11416 28 34945481
Hepatitis 31.57 19.27 39 11383 23865 34921644
Gamma-glutamyltransferase increased 31.30 19.27 43 11379 29188 34916321
Pain 31.11 19.27 14 11408 204661 34740848
Dysphagia 30.85 19.27 65 11357 62316 34883193
Hepatic cytolysis 30.14 19.27 30 11392 14466 34931043
Death neonatal 30.11 19.27 9 11413 353 34945156
Meningitis cryptococcal 30.04 19.27 15 11407 2389 34943120
Hepatomegaly 28.32 19.27 25 11397 10371 34935138
HIV infection 28.18 19.27 12 11410 1327 34944182
Low set ears 27.81 19.27 9 11413 460 34945049
Congenital anomaly 27.73 19.27 12 11410 1381 34944128
Anaemia macrocytic 26.79 19.27 15 11407 3011 34942498
Tuberculosis 26.15 19.27 22 11400 8555 34936954
Protrusion tongue 25.82 19.27 7 11415 192 34945317
Kaposi's sarcoma 25.75 19.27 10 11412 873 34944636
Hepatic cirrhosis 25.73 19.27 30 11392 17284 34928225
Congenital nose malformation 25.72 19.27 7 11415 195 34945314
Liver function test abnormal 25.04 19.27 40 11382 31034 34914475
Meconium ileus 24.88 19.27 5 11417 34 34945475
Febrile neutropenia 24.80 19.27 7 11415 136842 34808667
Synostosis 24.74 19.27 6 11416 104 34945405
Rash 24.57 19.27 140 11282 222612 34722897
Syphilis 24.37 19.27 8 11414 428 34945081
Hepatic steatosis 24.31 19.27 30 11392 18332 34927177
Hyperlactacidaemia 24.15 19.27 14 11408 3002 34942507
Dyspnoea 24 19.27 55 11367 376727 34568782
Aplasia cutis congenita 23.98 19.27 6 11416 119 34945390
Subchondral insufficiency fracture 23.72 19.27 4 11418 8 34945501
Loss of anatomical alignment after fracture reduction 23.72 19.27 4 11418 8 34945501
Oral candidiasis 23.24 19.27 24 11398 12086 34933423
Molluscum contagiosum 23.17 19.27 7 11415 285 34945224
Retinoblastoma 23.10 19.27 4 11418 10 34945499
Constipation 23.04 19.27 8 11414 136974 34808535
Acquired immunodeficiency syndrome 23.02 19.27 8 11414 510 34944999
Fracture malunion 22.82 19.27 4 11418 11 34945498
Disease progression 22.65 19.27 4 11418 108073 34837436
Anaemia neonatal 22.60 19.27 7 11415 310 34945199
Glycosuria 22.49 19.27 10 11412 1227 34944282
Blindness 22.33 19.27 26 11396 14960 34930549
Optic nerve cupping 22.25 19.27 5 11417 61 34945448
Product dose omission issue 21.92 19.27 6 11416 119705 34825804
Acute HIV infection 21.82 19.27 5 11417 67 34945442
Blood insulin increased 21.72 19.27 7 11415 353 34945156
Hepatitis C 21.66 19.27 21 11401 9809 34935700
Hepatitis cholestatic 21.42 19.27 19 11403 7928 34937581
Primary syphilis 21.12 19.27 4 11418 19 34945490
Hyperplasia adrenal 21.08 19.27 3 11419 0 34945509
Elbow synostosis 20.95 19.27 4 11418 20 34945489
Renal tubular disorder 20.89 19.27 15 11407 4628 34940881
Atrial fibrillation 20.84 19.27 7 11415 122386 34823123
Proteinuria 20.82 19.27 28 11394 18614 34926895
Umbilical hernia 20.80 19.27 15 11407 4662 34940847
Hepatic failure 20.69 19.27 39 11383 34492 34911017
Chronic hepatitis C 20.58 19.27 7 11415 418 34945091
Pulmonary tuberculosis 20.58 19.27 15 11407 4739 34940770
Embolism venous 20.55 19.27 10 11412 1506 34944003
Neutropenia neonatal 20.54 19.27 8 11414 704 34944805
CD4 lymphocytes increased 20.46 19.27 6 11416 220 34945289
Congenital tuberculosis 20.33 19.27 4 11418 24 34945485
Hypersplenism 20.22 19.27 7 11415 441 34945068
Hypercholesterolaemia 19.83 19.27 19 11403 8743 34936766
Congenital cytomegalovirus infection 19.68 19.27 4 11418 29 34945480
Product use in unapproved indication 19.52 19.27 7 11415 117492 34828017
Immune recovery uveitis 19.44 19.27 4 11418 31 34945478
Fanconi syndrome 19.35 19.27 10 11412 1710 34943799

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 1062.26 19.45 227 14229 4098 79725834
Virologic failure 811.55 19.45 181 14275 4010 79725922
Mitochondrial toxicity 796.14 19.45 169 14287 2945 79726987
Viral mutation identified 732.64 19.45 164 14292 3694 79726238
Drug resistance 652.40 19.45 256 14200 41957 79687975
Abortion spontaneous 541.88 19.45 203 14253 29304 79700628
Eyelid ptosis 495.91 19.45 149 14307 10895 79719037
Stillbirth 424.70 19.45 106 14350 3849 79726083
Progressive external ophthalmoplegia 395.45 19.45 83 14373 1362 79728570
Exposure during pregnancy 392.14 19.45 238 14218 100894 79629038
Pathogen resistance 350.62 19.45 122 14334 14220 79715712
Immune reconstitution inflammatory syndrome 343.23 19.45 119 14337 13722 79716210
Diplopia 328.34 19.45 147 14309 33319 79696613
Stevens-Johnson syndrome 306.24 19.45 147 14309 39019 79690913
Caesarean section 232.65 19.45 87 14369 12448 79717484
Abortion induced 231.27 19.45 75 14381 7034 79722898
Pregnancy 213.52 19.45 102 14354 26749 79703183
Foetal exposure during pregnancy 212.67 19.45 67 14389 5723 79724209
Acquired gene mutation 205.86 19.45 53 14403 2180 79727752
Portal hypertension 191.29 19.45 65 14391 7043 79722889
Maternal exposure during pregnancy 165.87 19.45 161 14295 136377 79593555
Viral load increased 150.67 19.45 44 14412 2904 79727028
Maternal drugs affecting foetus 126.60 19.45 34 14422 1649 79728283
Ultrasound antenatal screen 118.15 19.45 27 14429 666 79729266
Ophthalmoplegia 116.58 19.45 36 14420 2876 79727056
Hydrops foetalis 115.04 19.45 27 14429 751 79729181
Conjunctivalisation 114.72 19.45 16 14440 9 79729923
Nephropathy toxic 105.40 19.45 58 14398 20361 79709571
Trisomy 18 105.29 19.45 24 14432 585 79729347
Toxic epidermal necrolysis 102.57 19.45 76 14380 44505 79685427
Cleft lip and palate 102.03 19.45 24 14432 674 79729258
Alanine aminotransferase increased 98.79 19.45 134 14322 162436 79567496
Hepatic cytolysis 92.57 19.45 59 14397 27092 79702840
Blood HIV RNA increased 92.46 19.45 27 14429 1781 79728151
Dyslipidaemia 88.82 19.45 43 14413 11590 79718342
Vanishing bile duct syndrome 88.49 19.45 26 14430 1752 79728180
Lipoatrophy 86.76 19.45 21 14435 668 79729264
Aspartate aminotransferase increased 83.78 19.45 114 14342 138527 79591405
Hepatotoxicity 82.69 19.45 71 14385 51281 79678651
Product residue present 74.66 19.45 27 14429 3509 79726423
Postpartum sepsis 72.80 19.45 10 14446 4 79729928
Pulmonary tuberculosis 72.14 19.45 33 14423 7832 79722100
Pain 69.09 19.45 21 14435 703781 79026151
Premature delivery 67.83 19.45 46 14410 23421 79706511
Proteinuria 67.20 19.45 52 14404 32450 79697482
Hepatomegaly 66.79 19.45 42 14414 18832 79711100
CD4 lymphocytes decreased 66.61 19.45 23 14433 2611 79727321
Retinoblastoma 66.58 19.45 12 14444 83 79729849
Ulcerative keratitis 66.22 19.45 25 14431 3664 79726268
Fat tissue increased 65.69 19.45 18 14438 942 79728990
Drug ineffective 65.58 19.45 60 14396 1080853 78649079
Varices oesophageal 64.10 19.45 28 14428 5963 79723969
Nodular regenerative hyperplasia 63.79 19.45 19 14437 1342 79728590
Hepatitis 62.51 19.45 63 14393 55664 79674268
Blood lactic acid increased 62.48 19.45 35 14421 12709 79717223
Tuberculosis 59.32 19.45 36 14420 15162 79714770
Fall 56.82 19.45 10 14446 487619 79242313
Gamma-glutamyltransferase increased 56.24 19.45 59 14397 54621 79675311
Premature baby 55.02 19.45 22 14434 3758 79726174
Immune reconstitution inflammatory syndrome associated tuberculosis 54.08 19.45 15 14441 821 79729111
Eyelid scar 53.31 19.45 7 14449 0 79729932
Osteonecrosis 52.10 19.45 44 14412 31051 79698881
Multiple-drug resistance 50.97 19.45 27 14429 8781 79721151
Uveal prolapse 50.82 19.45 7 14449 3 79729929
Pre-eclampsia 50.67 19.45 25 14431 7016 79722916
Foetal death 50.38 19.45 26 14430 8018 79721914
Acute HIV infection 49.97 19.45 9 14447 62 79729870
Rash maculo-papular 49.79 19.45 56 14400 56022 79673910
Hepatic cirrhosis 49.66 19.45 45 14411 34861 79695071
Meningitis cryptococcal 49.63 19.45 20 14436 3486 79726446
Mitochondrial cytopathy 49.09 19.45 12 14444 398 79729534
Malaria 48.75 19.45 12 14444 410 79729522
Placental disorder 48.00 19.45 14 14442 919 79729013
Mitochondrial myopathy 47.57 19.45 11 14445 286 79729646
Glycosuria 47.29 19.45 17 14439 2171 79727761
Jaundice 46.90 19.45 53 14403 53296 79676636
Oligohydramnios 46.70 19.45 19 14437 3393 79726539
Dandy-Walker syndrome 45.81 19.45 8 14448 45 79729887
Pyrexia 43.87 19.45 240 14216 678469 79051463
Anaemia 43.87 19.45 178 14278 444837 79285095
Fanconi syndrome acquired 43.85 19.45 17 14439 2677 79727255
Pinealoblastoma 43.25 19.45 8 14448 65 79729867
Portal vein thrombosis 42.86 19.45 21 14435 5806 79724126
Ventricular septal defect 41.43 19.45 11 14445 510 79729422
Off label use 41.37 19.45 63 14393 907152 78822780
HIV infection 41.20 19.45 13 14443 1114 79728818
Blindness 41.18 19.45 37 14419 28346 79701586
Joint swelling 40.83 19.45 3 14453 288643 79441289
HIV peripheral neuropathy 40.78 19.45 7 14449 35 79729897
Eyelid oedema 39.95 19.45 27 14429 13660 79716272
Hepatic failure 39.48 19.45 52 14404 61160 79668772
Drug reaction with eosinophilia and systemic symptoms 39.02 19.45 53 14403 64191 79665741
Normal newborn 39.01 19.45 21 14435 7051 79722881
Live birth 36.60 19.45 29 14427 18715 79711217
Osteoporosis 36.50 19.45 47 14409 54065 79675867
Treatment noncompliance 36.20 19.45 46 14410 52222 79677710
Premature labour 35.66 19.45 21 14435 8369 79721563
Fatigue 35.63 19.45 72 14384 929655 78800277
Genotype drug resistance test positive 35.33 19.45 12 14444 1296 79728636
Dysphagia 35.13 19.45 72 14384 122064 79607868
Congenital anomaly 34.78 19.45 9 14447 377 79729555
Hypertriglyceridaemia 34.51 19.45 24 14432 12716 79717216
Neutropenia neonatal 34.32 19.45 6 14450 34 79729898
Hepatic steatosis 34.03 19.45 38 14418 37700 79692232
Lactic acidosis 33.89 19.45 52 14404 70307 79659625
Hypercholesterolaemia 33.29 19.45 30 14426 23065 79706867
Blood triglycerides abnormal 32.60 19.45 9 14447 484 79729448
Nasopharyngitis 32.31 19.45 4 14452 253877 79476055
Bone metabolism disorder 32.16 19.45 9 14447 509 79729423
Amniotic cavity infection 32.16 19.45 10 14446 817 79729115
Hyperlactacidaemia 31.95 19.45 17 14439 5578 79724354
Completed suicide 30.97 19.45 4 14452 245763 79484169
Hypotension 30.90 19.45 21 14435 440296 79289636
Conjunctival hyperaemia 29.78 19.45 15 14441 4398 79725534
Speech disorder developmental 29.69 19.45 9 14447 675 79729257
Abdominal discomfort 29.47 19.45 5 14451 250722 79479210
Placental insufficiency 29.15 19.45 10 14446 1113 79728819
Anaemia neonatal 29.13 19.45 5 14451 25 79729907
Astrocytoma malignant 28.96 19.45 5 14451 26 79729906
Hepatitis cholestatic 28.27 19.45 22 14434 13830 79716102
Developmental delay 28.25 19.45 10 14446 1221 79728711
Molluscum contagiosum 28.11 19.45 8 14448 481 79729451
Blood pressure increased 27.72 19.45 3 14453 211357 79518575
Hereditary optic atrophy 27.33 19.45 5 14451 38 79729894
Hyperplasia adrenal 27.33 19.45 5 14451 38 79729894
Lipase increased 26.96 19.45 23 14433 16443 79713489
Toxoplasmosis 26.90 19.45 12 14444 2685 79727247
Peripheral swelling 26.46 19.45 8 14448 269609 79460323
Spina bifida 26.37 19.45 6 14450 145 79729787
Loss of anatomical alignment after fracture reduction 26.07 19.45 4 14452 8 79729924
Optic nerve cupping 25.42 19.45 5 14451 58 79729874
Lymphadenopathy 25.14 19.45 39 14417 53208 79676724
Sinusitis 25.07 19.45 3 14453 195498 79534434
Meningitis tuberculous 24.69 19.45 9 14447 1196 79728736
Symblepharon 24.66 19.45 6 14450 195 79729737
Osteoporotic fracture 24.54 19.45 13 14443 4227 79725705
Dyspnoea 24.53 19.45 77 14379 856948 78872984
Pneumonia 24.50 19.45 52 14404 660194 79069738
Hepatitis C 24.47 19.45 19 14437 11906 79718026
Premature separation of placenta 24.39 19.45 9 14447 1237 79728695
Febrile neutropenia 24.26 19.45 6 14450 230993 79498939
Cytomegalovirus chorioretinitis 24.02 19.45 14 14442 5476 79724456
Ultrasound antenatal screen abnormal 23.70 19.45 5 14451 84 79729848
Congestive hepatopathy 23.69 19.45 13 14443 4534 79725398
Retinal vasculitis 23.67 19.45 9 14447 1344 79728588
Syphilis 22.81 19.45 7 14449 547 79729385
Drug-induced liver injury 22.68 19.45 42 14414 66075 79663857
Alopecia 22.45 19.45 7 14449 231348 79498584
Splenomegaly 22.42 19.45 23 14433 20731 79709201
Borderline leprosy 22.41 19.45 4 14452 26 79729906
Back pain 22.01 19.45 14 14442 304166 79425766
Disseminated tuberculosis 21.90 19.45 12 14444 4171 79725761
Product use in unapproved indication 21.87 19.45 9 14447 250350 79479582
Immune recovery uveitis 21.79 19.45 4 14452 31 79729901
Left ventricular dilatation 21.73 19.45 8 14448 1093 79728839
Chronic hepatitis C 21.68 19.45 7 14449 646 79729286
Strabismus 21.32 19.45 10 14446 2511 79727421
Brachydactyly 21.07 19.45 4 14452 38 79729894
Liver function test abnormal 20.93 19.45 40 14416 64435 79665497
Kwashiorkor 20.77 19.45 3 14453 3 79729929
Progressive multifocal leukoencephalopathy 20.76 19.45 22 14434 20578 79709354
Urinary tract infection 20.74 19.45 12 14444 274500 79455432
Gene mutation 20.71 19.45 10 14446 2676 79727256
Kaposi's sarcoma 20.65 19.45 7 14449 752 79729180
Constipation 20.51 19.45 13 14443 283037 79446895
Transaminases increased 20.49 19.45 35 14421 51708 79678224
Arthralgia 20.40 19.45 46 14410 571757 79158175
Congenital retinoblastoma 20.31 19.45 3 14453 4 79729928
Syncope 20.18 19.45 4 14452 179445 79550487
Fanconi syndrome 20.13 19.45 10 14446 2846 79727086
Therapeutic product effect decreased 19.85 19.45 3 14453 163860 79566072
Portal hypertensive gastropathy 19.78 19.45 8 14448 1406 79728526
Psychiatric decompensation 19.74 19.45 11 14445 3952 79725980
Induced labour 19.69 19.45 7 14449 865 79729067
Rash 19.67 19.45 175 14281 578183 79151749

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AG01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Non-nucleoside reverse transcriptase inhibitors
ATC J05AR05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000009948 Non-Nucleoside Reverse Transcriptase Inhibitors
FDA EXT N0000175460 Non-Nucleoside Analog
FDA EPC N0000175463 Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000190118 Cytochrome P450 3A Inducers
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:53756 reverse transcriptase inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D065701 Cytochrome P-450 CYP3A Inducers
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Lyell's toxic epidermal necrolysis, subepidermal type contraindication 23067006
Viral hepatitis C contraindication 50711007 DOID:1883
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Chronic type B viral hepatitis contraindication 61977001
Stevens-Johnson syndrome contraindication 73442001 DOID:0050426
Chronic hepatitis C contraindication 128302006
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Rhabdomyolysis contraindication 240131006
Eruption of skin contraindication 271807003 DOID:0050486
Breastfeeding (mother) contraindication 413712001
Prevention of HIV Infection after Exposure contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.01 acidic
pKa2 2.45 Basic
pKa3 1.74 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
400MG VIRAMUNE XR BOEHRINGER INGELHEIM N201152 March 25, 2011 RX TABLET, EXTENDED RELEASE ORAL 8460704 March 12, 2029 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Reverse transcriptase/RNaseH Enzyme INHIBITOR Ki 6.40 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein IC50 7.10 WOMBAT-PK
Pol polyprotein Enzyme IC50 7 CHEMBL
Reverse transcriptase Enzyme IC50 6.30 CHEMBL
Reverse transcriptase protein Unclassified Ki 5.40 CHEMBL

External reference:

IDSource
4020991 VUID
N0000148461 NUI
D00435 KEGG_DRUG
220988-26-1 SECONDARY_CAS_RN
4020991 VANDF
C0132326 UMLSCUI
CHEBI:63613 CHEBI
NEV PDB_CHEM_ID
CHEMBL57 ChEMBL_ID
DB00238 DRUGBANK_ID
D019829 MESH_DESCRIPTOR_UI
4463 PUBCHEM_CID
12676 IUPHAR_LIGAND_ID
6815 INN_ID
99DK7FVK1H UNII
224890 RXNORM
175112 MMSL
5168 MMSL
6060 MMSL
d04029 MMSL
006062 NDDF
108704001 SNOMEDCT_US
386898005 SNOMEDCT_US
725663003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-4050 TABLET 200 mg ORAL ANDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-4890 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-4890 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-6950 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 29 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 0597-0046 TABLET 200 mg ORAL NDA 27 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 0597-0046 TABLET 200 mg ORAL NDA 27 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 0597-0047 SUSPENSION 50 mg ORAL NDA 27 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 0597-0047 SUSPENSION 50 mg ORAL NDA 27 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 0597-0123 TABLET, EXTENDED RELEASE 400 mg ORAL NDA 35 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 0597-0123 TABLET, EXTENDED RELEASE 400 mg ORAL NDA 35 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0781-5893 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
Nevirapine Human Prescription Drug Label 1 31722-505 TABLET 200 mg ORAL ANDA 29 sections
Nevirapine Human Prescription Drug Label 1 31722-505 TABLET 200 mg ORAL ANDA 29 sections
Nevirapine Human Prescription Drug Label 1 33342-004 TABLET 200 mg ORAL ANDA 28 sections
Nevirapine Human Prescription Drug Label 1 33342-004 TABLET 200 mg ORAL ANDA 28 sections
Nevirapine Human Prescription Drug Label 1 33342-004 TABLET 200 mg ORAL ANDA 28 sections
NEVIRAPINE Human Prescription Drug Label 1 33342-238 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
NEVIRAPINE Human Prescription Drug Label 1 33342-238 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
NEVIRAPINE Human Prescription Drug Label 1 33342-238 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
NEVIRAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-131 TABLET 200 mg ORAL ANDA 27 sections
NEVIRAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-131 TABLET 200 mg ORAL ANDA 27 sections
nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 53104-0166 TABLET 200 mg ORAL ANDA 26 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 53808-0680 TABLET 200 mg ORAL ANDA 29 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 53808-0808 TABLET 200 mg ORAL NDA 31 sections
nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 53808-1069 TABLET 200 mg ORAL ANDA 28 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 54868-6370 TABLET, EXTENDED RELEASE 400 mg ORAL NDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 61442-470 TABLET, COATED 200 mg ORAL ANDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 64380-709 TABLET 200 mg ORAL ANDA 28 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 64380-709 TABLET 200 mg ORAL ANDA 28 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 65162-209 TABLET 200 mg ORAL ANDA 27 sections